Anixa Biosciences
ANIX
16 hedge funds and large institutions have $4.32M invested in Anixa Biosciences in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 0 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
23% more funds holding
Funds holding: 13 → 16 (+3)
1.11% more ownership
Funds ownership: 4.75% → 5.86% (+1.1%)
5% more capital invested
Capital invested by funds: $4.12M → $4.32M (+$198K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$427K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$263K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$127K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$73.7K |
| 5 |
Bank of New York Mellon
New York
|
+$4.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$7.27K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.85K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.07K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $2.52M | +$263K | +61,227 | +11% |
|
|
2
UBS Group
Zurich,
Switzerland
| $663K | +$127K | +29,550 | +21% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $391K | +$427K | +99,405 | New |
|
|
4
Northern Trust
Chicago,
Illinois
| $231K | +$73.7K | +17,147 | +41% |
|
5
BlackRock
New York
| $206K | +$1.13K | +263 | +0.5% |
|
|
6
Bank of New York Mellon
New York
| $169K | +$4.59K | +1,069 | +3% |
|
|
SBH
7
Segall Bryant & Hamill
Chicago,
Illinois
| $69K | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| $29K | -$1.07K | -250 | -3% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $16K | -$1.85K | -430 | -10% |
|
10
Morgan Stanley
New York
| $11K | +$4.59K | +1,068 | +65% |
|
|
11
JP Morgan Chase
New York
| $6K | -$7.27K | -1,692 | -52% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $5K | +$1.09K | +253 | +23% |
|
13
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | +$1.76K | +410 | New |
|
|
HNB
14
Huntington National Bank
Columbus,
Ohio
| – | +$172 | +40 | New |
|
ANIX Hedge Fund Activity: Q4 2018 in Review
16 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2018, worth a combined $4.32M — up 4.8% from $4.12M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANIX positions and 0 closed out — a net gain of 3 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $427K. The largest seller was JP Morgan Chase, cutting an estimated $7.27K.
- 16 institutional investors held Anixa Biosciences (ANIX) as of Q4 2018, up from 13 in Q3 2018.
- Funds reported $4.32M of Anixa Biosciences stock for Q4 2018, up 4.8% quarter-over-quarter.
- 3 funds opened new Anixa Biosciences positions in Q4 2018 and 0 closed out, a net change of +3 holders.
- The largest Anixa Biosciences buyer in Q4 2018 was Geode Capital Management, an estimated $427K added.
- The largest Anixa Biosciences seller in Q4 2018 was JP Morgan Chase, an estimated $7.27K sold.
Based on aggregated 13F filings for Q4 2018.